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(8.8% YS 42.7%). target lesion revascularizatron (4.7% vs 8.3%) and MACE (8.6% vs 
23.1%). Eight pts in the overlap SES group had Res within the stent margins; one case 
was subacute stent thrombosis, one case was focal and not at the overlap region, one 
had diffuse Res (3 undersized stents after severe dissection), and the five remaining 
cases had focal Ras within the overlap region. Conclusions Overlapping SES vs. CS in 
the SIRIUS trial was associated with (1) infrequent adverse clinical outcomes (death, MI, 
stent thrombosis, or aneurysms), (2) maintained striking improvement for SES in all effi- 
cacy measures, and (3) the site of SES Res was usually withrn the stent at the overlap 
region. Factors such as vessel tortuosity, local flow disturbances, drug dosing effects or 
stent-edge incomplete apposition may contribute to this apparent increased overlap zone 
Res. which may be partially resolved with the use of longer single SES and IVUS guid- 
ance. 
(@270 days) SES (N=533) Control (N=525) P-value 
Death 0 9% 0.6% ns 
Ml (all) 2.8% 3.2% “s 
Stent thrombosis (all) 0.4% 0.8% “s 
TLR 4.1% 16.6% <0.001 
TVR (non-TL) 3.2% 4.8% ns 
MACE 7.1% 18.9% <O.OOl 
NF 8.6% 21 .O% <O.OOl 
Table I 
TLR = target lesion revascularization, TVR = target vessel revascularization, MACE = 
mafor adverse cardiac events, TVF = target vessel failure 
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805-4 Late Incomplete Stent Apposition Following Sirolimus- 
Eluting Stent: Serial Quantitative Intravascular 
Ultrasound Analysis From the SIRIUS Trial 
Junva Ako, Yoshihiro Merino, Yasuhiro Honda, Shinjo Sonoda. Mitsuyasu Terashima, Ali 
Hassan, Martin 6. Leon, Jeffrey W. Moses, Steve Osterle, Charles L. Brown, Donald S. 
Bairn, Paul G. Yock, Peter J. Fitzgerald, the SIRIUS Investigators, Stanford University, 
Stanford, CA, Lenox Hill Hospital, New York, NY 
Background: Stent incomplete apposition (IA) at follow-up is reported in drug-eluting 
stents. The aim of this study was to clarify the morphometric IVUS characteristics of late 
IA as compared with persistent IA following sirolimus-eluting stents (SES) vs bare metal 
stems (EMS). 
Methods: IVUS data were obtained from SIRIUS, a prospective, randomized, multicenter 
trial. IA was defined as z-1 struts separated from vessel wall with evidence of blood 
speckle behind the struts. The maximal stenfflumen gap, maximal axial length, and arc 
degrees of incompletely apposed struts were quantified. IA index was defined as total 
lumen area divided by lumen area within the stent. Persistent IA was considered present 
when IA was observed at both baseline and &month follow-up. Late IA was defined as 
new IA detected only at follow-up. 
Results: Of 130 serial cases, there were 19 follow-up IA segments in 17 patients (BMS 6, 
SES 11) available for quantitative analysis. While persistent IA was observed in both 
groups (EMS 6, SES 4) late IA was seen only in SES. AVessel area was significantly 
larger in late IA than persistent IA (~~0.05) and 3 late IAs showed pathologtc positive 
remodeling (z-20% increase in vessel area compared to baseline). All persistent IAs were 
located at stent edges, whereas 77% of late IAs occurred at single or multiple mid-stent 
segments (~~0.05). 
Conclusions: The characteristic morphometric findings of late IA following SES may sug- 
gest different vessel wall biology of this phenomenon compared to persistent IA. 
persistent IA BMS persistent IA SES late IA SES 
(n=6) (n=4) (It=9) 
Gap, mm2 0.36+0.17 0.40*0.12 0.69eO.33 
Arc, * 107t22.5 97*14.0 145*53.1 
Length, mm 1.9eO.65 2.8il.7 4.2t3.4 
Follow-up lumen area, mm2 8.3+2.5 9.&l .4 11.0*2.r3 
Follow-up vessel area, mms 1 WA7.3 17.0r2.5 l&9+3.6 
Avessel area, mm2 -0.007+0.61 0.34*0.&3 2.6il .O 
IA index l.lt0.07 1.1*0.02 1.3*0.36 
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805-5 Do Overlapping Multiple Sirolimus-Eluting Stents 
Impact Angiographic and Clinical Outcomes? Insights 
From the SIRIUS Trial 
Giora Weisz, Jeffrey W. Moses, Jeffrey J. Popma, Greg Mishkel. Robert L. Wilensky, 
Barry Cohen, Hooman Madyoon. David Roberts, Martin B. Leon, Lenox Hill Hospital 
Heart and Vascular Institute of New York and Cardiovascular Research Foundation, New 
York, NY 
Background: Although previous clinical studies have demonstrated a dramatic reduction 
in subsequent restenosis (Res) after wolimus-elutrng stent (SES) implantation, links IS 
known about the impact of overlapping multrple stents on angiographic and clinical out- 
comes.Methods: In the randomized, double-blind SIRIUS trial, in longer lesions or to 
treat edge dissections, multiple overlapprng stents were implanted tn 33% of the SES pts 
(n=l76) and in 32% of the control bare stent (CS) pts (n=l68). Clinical and angiographlc 
findings, including the contribution of the overlap region to Res, were assessed. Results: 
Overlap SES and CS pts had similar reference vessel diameter (2.77 vs 2.80 mm), lesion 
length (18.2 vs 18.1 mm), pretreatment minimal luminal diameter (0.93 vs 0.94 mm), 
stent length (28.3 vs 27.8 mm), and stent overtap-segment length (4.6 vs 4.1 mm). There 
were no drfferences in safety outcomes Including In-hospital MACE (4.5% vs 4.2%) sub- 
acute stent thrombosis (I pt in each group, 0.6%) late stent thrombosis (none), and 
aneurysms (none). Anglographic and clinical efficacy were sfgnificantly better (pcO.001) 
in the SES vs. CS pts: in-lesion late loss (0.20 vs 0.93 mm), in-lesion binary restenosis 
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808-l Mobilized Bone Marrow Stem Cells Accelerate 
Reendothelialization, Reduce Vascular Inflammation, 
and Prevent Restenosis After Intravascular Radiation 
Hvun-Jai Cho. Hyo-Soo Kim, Dae-Hee Kim, Seil Oh, In-Ho Chae, Byung-Hee Oh, 
Myoung-Mook Lee, Young-Bae Park, Yun-Shik Choi, Seoul National University College 
of Medicine, Seoul, South Korea, Clinical Research Institute, Seoul National University 
Hospital, Seoul, South Korea 
Background: Stem cell therapy may provide new possibilities for the treatment of vascu- 
lar disorders. We investigated a role of mobilized stem cell in the healing process after 
intravascular radiation, the condition of few replicating endothelial cells in adjacent area. 
Methods: 1% cholesterol diet fed male New Zealand White rabbits with injured iliac 
artery were divided into two groups. The GM-CSF group (n=l5) received rhGM-CSF 
(6Qgiday) daily for 1 week, beginning 7 day before injury. Control group (n=lr3) received 
human albumin. One iliac artery was subjected to intravascular radiation via ‘ssRe-bal- 
loon and the contralateral iliac artery to balloon angioplasty control. Morphometry and 
immunohistochemistry were done. Peripheral blood mononuclear cells (MNCs) were iso- 
lated from blood just before vessel harvest, analyzed FACS and cultured for 4 weeks. 
Results: In control group, intravascular radiation therapy reduced neointimal hyperplasia 
(0.09*0.03 vs 0.26+0.11 rnd, P<O.Ol) but delayed reendothalialization and promoted 
inflammatory cell infiltration. After GM-CSF pretreatment, reendothelialization index 
(defined as CD31 stained endoluminal perimeter) recovered to al*13 % (n=7), whereas 
30+11 % in the control radiatron group (n=9) (PcO.01) and RAM1 l-positive cell (mac- 
rophage) infiltration reduced in media at 14 days. (12+7 vs 29+10 %, PcO.01) Also, addi- 
tional significant reduction in neointimal thickening was observed. (0.04+0.01 vs 
0.09iO.03 mm’, P<O.Ol) FACS analysis showed that 24% of MNCs were positive for 
CD31 and 13% positive for CD34 in the GM-CSF group but all negative in the control 
group. Cultured cells were assayed with costainrng with Dil/acLDL and FITC-confugated 
BS Lectin as endothelial progenitor cells, also double positive stained cell count was srg- 
nificant higher in GM-CSF group. (33*15 vs 6+4 imr?, 2 weeks; 446ilOl vs 5&29 / 
mn-?, 4 weeks after culture, P~o.01) 
Conclusions: GM-CSF pretreatment mobilizes stem cells, accelerates reendothelializa- 
tion and reduces inflammatory cells infiltration after intravascular radiation therapy, which 
suggests that stem cell therapy is a promising strategy for enhanong vascular healing 
process after angioplasty. 
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808-2 Activation of Peroxisome Proliferator-Activated 
Receptor and Gamma Inhibits Neointimal Formation in a 
Diabetic Rat Carotid Artery Injury Model 
Kai Wanq Liming Fan, Zhongmin Zhou, Farhad Forudi, Xiaorong Zhou, A. Michael 
Lincoff, Eric J. Topol, Marc S. Penn, The Cleveland Clinic Foundation, Cleveland, OH 
Background: Peroxisome Prokferator-Activated Receptor y (PPARy) is member of the 
nuclear receptor superfamily of ligand-dependent transcription factors. Thiazolidinedi- 
ones, which are anti-diabetic agents and high-affinity ligands for PPARy, have been 
shown to inhibit the growth of vascular smooth muscle cells. In this study, the role of 
PPARy on neointimal formation was studied in a diabetic rat carotid artery injury model. 
Methods and Results: Balloon injury of carotid artery was performed in the Zucker fat 
rats (diabetic) and lean rats (non-diabetic) using the standard method. In treatment 
groups, rosiglitazone (20mgikglday) PPARy agonist, was grven orally 1 week before 
injury through the 21 days follow-up. The animals were sacrificed after 21 days, and mor- 
ohometric analvsis was performed. Lioids and alucose assav was DerfOrmed at baseline _ 
and 21 days. Neorntimal formation was significantly decreased by the administration of 
roskalitazone. but onlv in the diabetic rat cohort (Table). There was no difference of lioids 
and glucose levels between baseline and 21 days in the diabetic rats. Conclusion: The 
activation of PPAW inhibits neointimal hyperplasia in a diabetic rat carotid arlery injury 
